Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.
about
Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectivesTargeted therapy of gastrointestinal stromal tumoursChronic myeloid leukemia: reminiscences and dreamsEosinophilia in Hematologic DisordersTreating adults with acute lymphocytic leukemia: new pharmacotherapy options.Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRABeyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.Allogeneic Hematopoietic Stem Cell Transplantation for a BCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic LeukemiaPonatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndromeSynergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816VPonatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.Therapy of chronic myeloid leukemia: twilight of the imatinib era?Recent advances in the treatment of gastrointestinal stromal tumors.Acute myeloid leukemia associated with FGFR1 abnormalities.Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome.The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells.Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report.Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib.Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid.Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.
P2860
Q26741009-6DBE1460-1253-4090-97C8-6086FAEBC0CAQ26745633-DBBA76F7-6B77-4E66-B9B9-091E0D3AE67BQ26748769-10549ADE-4851-4191-B719-DA8482616B33Q26799611-1FDEC9D6-ABD8-4D76-9325-7DE99774928DQ30243925-C99020BA-1A8C-4A4F-84C4-2A808E71A4D8Q33441382-A433D71A-619E-4F33-AC2C-DF5E64DFCC25Q35114558-A22CABDE-CF32-42E6-9F86-FB696AD0C1A4Q36125976-D7F2C753-EA3B-4E5D-8B37-4311B9262B35Q36307383-63C6772D-7453-4563-B2C1-B8E1AB222075Q36498390-B7C8EF62-E79A-498A-902B-62E9F7529082Q37144902-BFDDFD5D-AD07-4B4D-9A97-3271AC9715F3Q37591364-B82073AE-2677-411D-82BE-0303E0FA7E23Q37593435-86B6AF7B-F8BC-406D-8883-9FCC1FB8F1C3Q37704347-B444452D-3B5C-4358-BF8A-EFACE28FA1FEQ38100975-C3766CB9-BE96-493C-A774-029005D56A10Q38131481-D21F262A-E3AD-4551-B7D8-E779B6E33149Q38829019-93713C25-B375-40D7-BCDA-69BE86E928AEQ38833773-D3B53DDF-1CC0-49E8-86D5-A162F0DAA6BBQ38941959-11C025D7-9D21-4105-A5EF-F547C48354BCQ40974422-E0F9FF6C-F318-46A1-ADDF-EAA8D06D8242Q41402735-25A92A74-BF11-4CEA-9C14-49BF035FEA62Q47144472-0E5FD65B-C0FC-44CE-9006-155D2D6A5856Q48109911-8A2BE041-A044-4B17-8CCD-133654B5B2C6Q48227433-8C5A3C54-E4F4-4F7C-9119-0DA0D3159F5AQ48274819-FC03474F-C7CF-405A-A623-7BF66CD7CD54Q54450582-3D162FB5-DC80-4848-B831-7BC4BA642443Q55362356-93A4C92F-BFC4-48E9-B75E-F504FE8D8B03
P2860
Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Ponatinib is active against im ...... FGFR1-derived fusion kinases.
@en
Ponatinib is active against im ...... FGFR1-derived fusion kinases.
@nl
type
label
Ponatinib is active against im ...... FGFR1-derived fusion kinases.
@en
Ponatinib is active against im ...... FGFR1-derived fusion kinases.
@nl
prefLabel
Ponatinib is active against im ...... FGFR1-derived fusion kinases.
@en
Ponatinib is active against im ...... FGFR1-derived fusion kinases.
@nl
P2093
P2860
P50
P356
P1433
P1476
Ponatinib is active against im ...... FGFR1-derived fusion kinases.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2012.8
P577
2012-01-17T00:00:00Z
P5875
P6179
1045977157